When Charles Schulz became Chairman of the Department of Psychiatry at the University of Minnesota Medical School in 1999, he came with a plan. I wrote about it in a series back in April if you’re not familiar with the story: Academic·Industrial·Complex I… Academic·Industrial·Complex II… Academic·Industrial·Complex III… By that time, it was a plan following […]
I haven’t followed the goings-on about the FDA appointee Dr. Robert Califf and his industry connections. I’ve been tangled up in other things. To be honest, my beefs about the FDA aren’t as strong as many who are interested in these matters. I accept that the mandate of the FDA was originally Safety and that […]
I’ve had a touch of paralysis writing this blog lately. At first I thought it had to do with our article being published [Restoring Study 329…] and the press responses that went with that [in the news…]. Then I thought maybe it had something to do with a few of the responses to the article […]
Want to understand drug pricing? Tell pharma to open its books Pharmalot by Ed Silverman September 30, 2015 Like it or not, Martin Shkreli is the new face of pharma. And for an industry already struggling with an image problem over the rising costs of prescription drugs, companies are going to have a hard time distancing […]